Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kaleida Capital is a venture capital firm founded by Dr. Ariane Tom in the United States. The firm focuses on investing in early-stage companies that are pioneering advancements in neurotechnology and artificial intelligence. Since its inception, Kaleida Capital has aimed to support the development of brain-inspired technologies that enhance human capabilities and enable precision medicine.
The organization has built a portfolio that reflects its commitment to innovation in the neurotechnology and AI sectors. Kaleida Capital's team comprises experts in these fields, allowing them to identify and nurture promising startups. The firm actively seeks to invest in companies that are developing breakthrough technologies, particularly in neural engineering and brain-computer interfaces.
As of now, Kaleida Capital has established a significant presence in the venture capital landscape, focusing on sectors that are critical to the future of healthcare and human performance. Their investment strategy is designed to foster the growth of technologies that can transform lives and improve health outcomes.
Kaleida Capital invests primarily in the neurotechnology and artificial intelligence sectors. The firm targets early-stage companies at various funding stages, including pre-seed, seed, seed-plus, and Series A. Their investment strategy emphasizes neural data infrastructure, human performance, and digital interfaces, which are crucial for the development of advanced technologies in these fields.
The organization is particularly interested in companies that are creating breakthrough technologies in neural engineering, brain-computer interfaces, and deep AI applications. Kaleida Capital looks for founders who demonstrate a strong vision and the capability to execute on innovative ideas that can significantly impact the market.
Investment checks typically align with early-stage funding requirements, allowing Kaleida Capital to support startups as they navigate their initial growth phases. The firm is committed to identifying and backing companies that are poised to lead in the neurotechnology and AI sectors.
Kaleida Capital's portfolio features a diverse range of innovative companies, including:
This portfolio illustrates Kaleida Capital's focus on supporting companies that are at the forefront of technological advancements in neurotechnology and AI.
Dr. Ariane Tom - Founder & Managing Director. Dr. Tom has a PhD and extensive experience in neurotechnology and AI, leading the firm’s vision and investment strategy.
Dr. Kevin Carlberg - Venture Partner. Dr. Carlberg brings expertise in technology commercialization and has a strong background in venture capital.
Dr. Srihari Sritharan - Venture Fellow. Dr. Sritharan specializes in neural engineering and contributes to the evaluation of potential investments.
Dr. Sharena Rice - Venture Fellow. Dr. Rice focuses on AI applications and supports portfolio companies in scaling their technologies.
Chad Sadili - Operations Associate and Executive Assistant. Chad manages operational tasks and supports the team in various capacities.
To pitch Kaleida Capital, founders should visit their website and submit a detailed pitch deck. The deck should include information about the technology, market opportunity, and team qualifications. A warm introduction is preferred but not mandatory. Founders can expect a response within a few weeks after submission.
In recent months, Kaleida Capital has made significant investments in innovative companies within the neurotechnology and AI sectors. Notable investments include a computational neuroimaging platform aimed at enhancing drug development for mental health conditions and a brain-computer interface technology designed to restore motor functions in patients with severe disabilities.
The firm continues to curate a portfolio that reflects its commitment to supporting groundbreaking technologies that can transform healthcare and human performance.
What are Kaleida Capital's investment criteria?
Kaleida Capital focuses on early-stage companies in the neurotechnology and AI sectors. They look for startups that are developing breakthrough technologies, particularly in neural engineering and brain-computer interfaces.
How can I pitch to Kaleida Capital?
Founders can submit their pitches through the Kaleida Capital website. It is recommended to include a detailed overview of the technology, market potential, and team background in the pitch deck.
What makes Kaleida Capital different from other investors?
Kaleida Capital specializes in neurotechnology and AI, providing not only capital but also expertise in these fields. Their team comprises professionals with deep knowledge and experience, which can be invaluable for portfolio companies.
What is the geographic focus of Kaleida Capital?
The firm primarily invests in companies based in the United States, aligning with their goal to support local innovations in neurotechnology and AI.
What is the typical check size for investments?
Kaleida Capital invests at various early stages, including pre-seed, seed, seed-plus, and Series A, with check sizes that are appropriate for these stages.
What kind of post-investment support does Kaleida Capital provide?
Kaleida Capital engages actively with its portfolio companies, offering mentorship and operational support to help them scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.